A Study of GZR18 Injection in Chinese Patients With Type 2 Diabetes Mellitus

NCT06256549 · Unknown status

Last updated 2026-05-28

This clinical trial is testing the effects of GZR18 injection compared to Semaglutide in adults with Type 2 diabetes over 24 weeks.

Status Unknown status The sponsor has not confirmed the status recently.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 272 people

Who can join Ages 18–75 · all sexes

Timeline Started 2023-08 · est. completion 2024-07

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT06256549 ↗

Description as written by the study sponsor.

This study was a multicenter, randomized, parallel and controlled study in adult patients with T2DM to evaluate the efficacy, safety (including immunogenicity) and pharmacokinetics of GZR18 injection in adult patients with T2DM.

Treatments tested

GZR18 Drug

Titrated to low dose or middle or high dose
Semaglutide Drug

Titrated to 1.0 mg once a week

Main thing measured	Compared with Semaglutide, the changes of HbA1c compared with baseline after continuous administration of GZR18 injection for 24 weeks
Sponsor	Gan and Lee Pharmaceuticals, USA
Conditions studied	Type 2 Diabetes
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06256549 ↗